Entero Healthcare Solutions Limited, established in 2018, is a prominent healthcare supply chain solutions provider and ranks among India's top three healthcare product distributors by revenue. The company operates as a technology-driven, integrated platform offering comprehensive commercial, supply chain, and distribution services across the healthcare ecosystem. Entero Healthcare Solutions was founded with the objective of building an organized, pan-India, technology-driven and integrated healthcare products distribution platform that adds value to the entire healthcare sector. The company boasts a wide operational presence across India, reaching 540 districts through its physical warehouses in 39 cities. Its business involves trading pharmaceutical and surgical products to retail pharmacies, hospitals, healthcare product manufacturers, and healthcare clinics. Additionally, it distributes medical devices, over-the-counter medical products, nutraceuticals, and vaccines, along with offering essential health products like nebulizers, digital thermometers, blood pressure monitors, and adult diapers.
As of recent data, Entero Healthcare Solutions has a market capitalization of ₹5,364 crore, with reported revenue of ₹5,096 crore and a profit of ₹107 crore. For the full financial year ended March 2025, the company witnessed a substantial increase in net profit, rising by 142.44% to ₹94.82 crore compared to ₹39.11 crore in the previous year. Revenue also saw a significant growth of 29.92%, reaching ₹5,095.78 crore from ₹3,922.31 crore in FY24.
The company's quarterly performance has been equally impressive. In Q4 FY25, net profit grew by 22.51% to ₹25.69 crore from ₹20.97 crore in Q4 FY24, with sales increasing by 29.48% to ₹1,339.06 crore from ₹1,034.18 crore. For Q3 FY25, net profit surged by an exceptional 275.22% to ₹25.44 crore, compared to ₹6.78 crore in Q3 FY24, while sales rose by 36.91% to ₹1,359.00 crore from ₹992.63 crore.
- Market Capitalization: ₹5,364 Crore (as of recent data)
- Promoter Holding: 52.4%
- Recent Revenue: ₹5,096 Crore
- Recent Profit: ₹107 Crore
- FY25 Net Profit: ₹94.82 Crore (up 142.44% YoY)
- FY25 Revenue: ₹5,095.78 Crore (up 29.92% YoY)
- Q4 FY25 Net Profit: ₹25.69 Crore (up 22.51% YoY)
- Q4 FY25 Revenue: ₹1,339.06 Crore (up 29.48% YoY)
- Q3 FY25 Net Profit: ₹25.44 Crore (up 275.22% YoY)
- Q3 FY25 Revenue: ₹1,359.00 Crore (up 36.91% YoY)
- Current Stock Price: ₹1,212
- 52-Week High: ₹1,584
- 52-Week Low: ₹1,060
- P/E Ratio: 55.6
- Book Value: ₹396
- Price to Book Value Ratio: 3.11
- Dividend: Not currently paying dividends.
Entero Healthcare Solutions has achieved significant financial milestones, reporting over ₹5,000 crores in revenue and a profit after tax exceeding ₹100 crores. This growth is driven by a consistent 30% year-on-year expansion, fueled by strategic acquisitions and an enlarged geographic footprint. The company is actively focused on enhancing operational efficiency, aiming to reduce working capital days to 60. This initiative is expected to significantly boost cash flow and support ambitious growth targets of 25% to 30% CAGR, while maintaining strong EBITDA margins through the strategic use of technology for improved distribution.
The company's registered office is located at Plot # I-35 Bldg-B Ind. Area, Phase-I 13/7 Mathura Road, Faridabad, Haryana, 121003.
The company's strategy revolves around being a comprehensive distributor of healthcare products. Its portfolio includes pharmaceutical products, surgical products, medical devices, over-the-counter medical products, nutraceuticals, and vaccines. Entero Healthcare Solutions serves a diverse customer base comprising retail pharmacies, hospitals, healthcare product manufacturers, and healthcare clinics.
Entero Healthcare Solutions is positioned for continued growth in India's expanding healthcare sector. The company's strategic focus on operational excellence, technology adoption, and geographical expansion, coupled with its robust financial performance, underpins its ability to capitalize on future market opportunities. The target of reducing working capital days to 60 and achieving a 25-30% CAGR are key strategic objectives.
- CFO Change: The Board of Directors accepted the resignation of Chebolu Venkataramana Ram as Chief Financial Officer, effective April 10, 2025. Balakrishnan Natesan Kaushik has been approved as the new CFO, effective April 11, 2025.
- ESOP Grant: On June 18, 2025, the company granted 5,900 Employee Stock Options (ESOPs) at ₹998 each under the 2023 Employee Stock Option Plan.
Entero Healthcare Solutions holds a strong position in the Indian healthcare distribution market:
- It ranks among the top three healthcare products distributors in India by revenue.
- It possesses the largest hospital customer network among pharmaceutical product distributors in India.
- It is among the top three healthcare products distributors with a wide network reach to retail pharmacies.
- The company achieved the fastest scale-up of operations among healthcare products distributors in India during the FY19-FY22 period.
Entero Healthcare Solutions was originally incorporated as a private limited company on January 10, 2018, and was subsequently converted to a public limited company on August 7, 2023.
Entero Healthcare Solutions' strong financial trajectory, strategic market positioning in India's healthcare distribution sector, and commitment to technology-driven solutions make it a compelling entity to watch within the growing Indian healthcare industry.
